Richard Whitcomb — President and CEO. Rick’s background is in operations, services, and finance. Prior to joining BiOptix, Rick was Senior Manager of the On Site Services business for Agilent Technologies Electronic Measurement Group. His background also includes several years of Corporate Development experience for Agilent and Hewlett-Packard Co., and he was formerly Operational CFO for the Communications Network Solutions business unit at Agilent. Rick brings substantial international experience, having spent five years living and working in Europe for Agilent and Hewlett-Packard Co. During his career, he has worked with scientists in Agilent Labs and HP Labs to move promising new technologies from the lab into commercialization, and ultimately into the hands of customer. Rick holds a Master of Science in Finance and Econometrics from The University of Colorado and a Bachelor of Science in Economics from The University of Minnesota.
Marty Stanton — CSO. Marty has held key leadership roles in biotechnology companies that have translated novel technologies into products to significantly improve patient care. Previously, Marty was the CSO and COO at SomaLogic, where he led the development of SomaLogic’s aptamer-based biomarker discovery platform. Prior to SomaLogic, Marty co-founded Dexela in 2005 to develop three-dimensional medical imaging for the early detection of cancer. While at Dexela, he served as the President and Head of Research and Development. In 2001, Marty co-founded Archemix Corp., a biopharmaceutical developing aptamer therapeutics located in Cambridge, Massachusetts. While at Archemix, Marty held a number of positions, including President and Executive Vice President. Prior to Archemix, Marty led an applied science research group at Brandeis University that developed a diverse array of applications, including proteomic technologies, x-ray crystallography detectors, and methods and instrumentation for medical imaging.
Marty received his PhD from Brandeis University in Biophysics.
Ken Wilczek — Vice President of Sales and Marketing. In addition to senior leadership and consulting roles both inside and outside of life sciences, prior to joining BiOptix, Ken was General Manager, Research Antibodies for Thermo Fisher Scientific. In this role, Ken had commercial responsibility for the Thermo Scientific antibody and high content analysis businesses and led the integration of ABR—Affinity BioReagents into the company post-acquisition. Prior to joining Thermo Fisher Scientific, Ken was the President of ABR—Affinity BioReagents, a manufacturer of research antibodies and custom antibody solutions. Ken was instrumental in growing the company and led the expansion of both the product line as well as global sales channels, ultimately positioning the company for divestment in 2008. Ken was also the General Manager for IHS Health Group and related divisions, a SaaS publisher to the life science, medical device and pharmaceutical industries. In addition, Ken held general management roles at Johnson & Johnson, focusing on international market and business development. Ken holds a Master of International Management degree from Thunderbird School of Global Management and a Bachelor of International Business Administration from The University of Denver.
Slava Petropavlovskikh — Director of Research and Development, Co-Founder, BiOptix. Slava is a dual degree graduate in Applied Mathematics (M.S. – Military Academy) and Applied Physics (M.S. – Moscow Institute of Physics and Technology, Moscow, Russia, Aerospace Department). He is a published expert and patent holder in applied physics, optical effects and signal manipulation and a former Science and Technology Manager at Ionics Sievers.
Kevin Ryan — Director of Engineering. Kevin brings over thirteen years of engineering experience to BiOptix. His expertise is in mechanical design, modeling, simulation and product development. Prior to joining BiOptix, Kevin focused on testing for aerospace applications with an emphasis on cryogenic temperatures. He has published papers on topics ranging from microcrack fracture toughness to bioaerosol inactivation using irradiation. Kevin holds both a Master of Science and a Bachelor of Science in Mechanical Engineering from the University of Colorado, Boulder.
1775 38th St.
Boulder, CO 80301 USA
November 17 - 19, 2014
ICBS 3rd Annual Conference
November 17 - 19, 2014
San Francisco, CA
Antibody Engineering Summit
December 7 - 11, 2014
Huntington Beach, CA